[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100391962":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":25,"centralContacts":30,"locations":36,"responsibleParty":54,"collaborators":25,"id":58,"slug":59,"hasResults":60,"nctId":61,"briefTitle":62,"officialTitle":62,"acronym":25,"eligibilityCriteria":63,"healthyVolunteers":64,"sex":65,"minAge":66,"maxAge":25,"enrollmentInfo":67,"targetDuration":25,"studyType":70,"phases":71,"briefSummary":73,"conditions":74,"keywords":25,"overallStatus":38,"whyStopped":25,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":85},{"fullName":5,"class":6},"Stanford University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Arm-1","EXPERIMENTAL","20 participants will be recruited, inject with radiopharmaceutical, and imaged on the 3T PETMR with PET insert.",[13],"Diagnostic Test: Injected radiotracer with PET Insert",{"label":15,"type":10,"description":16,"interventionNames":17},"Arm-2","20 participants will be recruited from other imaging studies that have been already injected (pre-injected) with a radiopharmaceutical. These subjects wont receive an additional injection of radiopharmaceutical.",[18],"Diagnostic Test: Pre-injected group with PET insert",[20,26],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DIAGNOSTIC_TEST","Injected radiotracer with PET Insert","1. Informed consent will be obtained before beginning any study procedures.\n2. Participants will receive a small quantity of an FDA approved radiotracer. The PET insert is placed within a 3T MRI scanner, where PET and MRI imaging will be completed.",[9],null,{"type":21,"name":27,"description":28,"armGroupLabels":29,"otherNames":25},"Pre-injected group with PET insert","1. Informed consent will be obtained before beginning any study procedures.\n2. Participants who have received radiotracer for another PET imaging system. The PET insert is placed within a 3T MRI scanner, where PET and MRI imaging will be completed.",[15],[31],{"name":32,"role":33,"phone":34,"phoneExt":25,"email":35},"Paul Newswanger","CONTACT","(650) 736-1349","pdn@stanford.edu",[37],{"facility":5,"status":38,"city":39,"state":40,"zip":41,"country":42,"countryCode":43,"cosmosGeoPoint":44,"geoPoint":49,"contacts":50},"RECRUITING","Palo Alto","California","94305","United States","US",{"type":45,"coordinates":46},"Point",[47,48],-122.14302,37.44188,{"lat":48,"lon":47},[51],{"name":52,"role":33,"phone":53,"phoneExt":25,"email":35},"Paul Newswanger, MPH","650-736-1349",{"type":55,"investigatorFullName":56,"investigatorTitle":57,"investigatorAffiliation":5,"oldNameTitle":25,"oldOrganization":25},"PRINCIPAL_INVESTIGATOR","Craig Levin","Professor, Radiology\u002F Nuclear Medicine","100391962","clinical-translation-of-a-novel-brain-pet-insert-for-simultaneous-petmr-100391962",false,"NCT04383808","Clinical Translation of a Novel Brain PET Insert for Simultaneous PET\u002FMR","Inclusion Criteria:\n\n1. Whole body radiation dose within the last year of less than 5000 mrem\n2. Subjects intended for injected tracer studies (not associated with another study) must be willing\u002Fable to undergo injection of 6-12 mCi of either FDG or Neuraceq radiotracer. Both tracers are FDA approved\n3. Subjects will be at least 21 years of age\n4. Subject provides written informed consent\n5. Subject is deemed healthy by the PI by via self-reported questionnaire\n\nExclusion Criteria:\n\n1. For patients who will be receiving a tracer injection, no known allergy to the imaging agents\n2. Participant has a history of or current diagnosis of cancer\n3. Participant is pregnant or nursing\n4. Metallic implants (contraindicated for MRI)",true,"ALL","21 Years",{"count":68,"type":69},40,"ESTIMATED","INTERVENTIONAL",[72],"NA","The primary goal of this project is to study the feasibility of a brain-dedicated PET insert for an MR scanner for simultaneous acquisition of PET\u002FMR images of human brains. The study will also allow us to compare the imaging performance of the investigator's brain-dedicated PET insert against a commercial whole-body permanently integrated PET\u002FMRI system using a common radiopharmaceutical.",[75],"Brain Disease","2025-04-03",{"date":78,"type":79},"2025-04-06","ACTUAL",{"date":81,"type":79},"2025-04-01",{"date":83,"type":69},"2028-03-31",{"name":5,"class":6},1]